128 related articles for article (PubMed ID: 37683502)
1. A near-infrared fluorescence-enhancing plasmonic biosensing microarray identifies soluble PD-L1 and ICAM-1 as predictive checkpoint biomarkers for cancer immunotherapy.
Lin Z; Liu M; Xing W; Wang F; Zhang H; Wei X; Schmitthenner H; Xie X; Xia X; Yang J
Biosens Bioelectron; 2023 Nov; 240():115633. PubMed ID: 37683502
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
Qian X; Chen H; Tao Y
Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
[TBL] [Abstract][Full Text] [Related]
3. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
[TBL] [Abstract][Full Text] [Related]
4. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
5. Nanophotonic immunoarray with electrochemically roughened surfaces for handheld detection of secreted PD-L1 to predict immuno-oncology efficacy.
Dey S; Koo KM; Ahmed E; Trau M
Lab Chip; 2023 Jul; 23(15):3443-3452. PubMed ID: 37417778
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma.
Tatarova Z; Blumberg DC; Bensen A; Mills GB; Jonas O
Cells; 2023 Jan; 12(2):. PubMed ID: 36672243
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
9. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
11. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer.
He Y; Zhang X; Zhu M; He W; Hua H; Ye F; Zhou X; Chen N; Li Y; Zhong W; Wu G; Cai H; Jiang W
J Transl Med; 2023 Jan; 21(1):25. PubMed ID: 36639643
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
13. A Dual-Channel Intelligent Point-of-Care Testing System for Soluble Programmed Death-1 and Programmed Death-Ligand 1 Detection Based on Folding Paper-Based Immunosensors.
Xing Y; Liu J; Luo J; Ming T; Yang G; Sun S; Xu S; Li X; He E; Kong F; Yan S; Yang Y; Cai X
ACS Sens; 2022 Feb; 7(2):584-592. PubMed ID: 35060694
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study.
Yang J; Hu M; Bai X; Ding X; Xie L; Ma J; Fan B; Yu J
Medicine (Baltimore); 2019 Sep; 98(39):e17231. PubMed ID: 31574833
[TBL] [Abstract][Full Text] [Related]
15. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
16. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
17. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
[TBL] [Abstract][Full Text] [Related]
18. Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers.
Mohanty SK; Mishra SK; Amin MB; Agaimy A; Fuchs F
Adv Anat Pathol; 2023 May; 30(3):174-194. PubMed ID: 37037418
[TBL] [Abstract][Full Text] [Related]
19. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
[TBL] [Abstract][Full Text] [Related]
20. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J; Mahoney KM; Giobbie-Hurder A; Zhao F; Lee S; Liao X; Rodig S; Li J; Wu X; Butterfield LH; Piesche M; Manos MP; Eastman LM; Dranoff G; Freeman GJ; Hodi FS
Cancer Immunol Res; 2017 Jun; 5(6):480-492. PubMed ID: 28522460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
